Company Overview and News

 
INGENICO GROUP: First Quarter 2018: Performance consistent with our full-year expectations

2018-04-25 globenewswire
Return to growth as early as Q2'18, with acceleration in the second half of the year
Upvote Downvote

 
INGENICO GROUP : Premier Trimestre 2018 : Une performance conforme à nos attentes

2018-04-25 globenewswire
Ingenico Group (Euronext : FR0000125346 - ING), leader mondial des solutions de paiement intégrées, publie aujourd'hui son chiffre d'affaires du premier trimestre 2018.
Upvote Downvote

 
INGENICO GROUP: Information related to the Combined Annual General Meeting of May 16th, 2018

2018-04-25 globenewswire
The Shareholders of Ingenico Group (Euronext : FR0000125346 - ING) are invited to participate to the Combined Annual General Meeting (ordinary and extraordinary) which will take place on May 16th, 2018 at 10:30 a.m. (Paris time) at the Maison des Arts et Métiers- 9bis avenue d'Iéna-75116 PARIS.
Upvote Downvote

 
INGENICO GROUP : Mise à disposition des informations relatives à l'Assemblée Générale Mixte du 16 mai 2018

2018-04-25 globenewswire
Les actionnaires de la Société Ingenico Group (Euronext : FR0000125346 - ING) sont invités à une Assemblée Générale Mixte Ordinaire et Extraordinaire qui se tiendra le mercredi 16 mai 2018, à 10h30, à la Maison des Arts et Métiers- 9 bis avenue d'Iéna- 75116 PARIS.
Upvote Downvote

 
INGENICO GROUP : Déclaration des opérations d'achats d'actions réalisées dans les conditions de l'article 5 §2 du règlement (UE) n° 596/2014 du 16 avril 2014 sur les abus de marché

2018-04-23 globenewswire
Conformément à la réglementation applicable, Ingenico Group déclare avoir effectué les opérations d'achat d'actions suivantes dans les conditions de l'article 5 §2 du règlement (UE) n°596/2014, du 16 avril 2018.
Upvote Downvote

 
Commerce Commission reviews Paymark acquisition

2018-04-20 nbr.co.nz
France’s Ingenico Group has sought clearance from the Commerce Commission to acquire electronic point of sale terminals operator Paymark’s New Zealand network.
Upvote Downvote

 
INGENICO GROUP : Mise à disposition du document de référence 2017

2018-04-18 globenewswire
Ingenico Group (Euronext : FR0000125346 - ING) annonce que son document de référence 2017 a été déposé auprès de l'Autorité des Marchés Financiers (AMF) ce jour.
Upvote Downvote

 
INGENICO GROUP : Déclaration des opérations d'achats d'actions réalisées dans les conditions de l'article 5 §2 du règlement (UE) n° 596/2014 du 16 avril 2014 sur les abus de marché

2018-04-16 globenewswire
Conformément à la réglementation applicable, Ingenico Group déclare avoir effectué les opérations d'achat d'actions suivantes dans les conditions de l'article 5 §2 du règlement (UE) n°596/2014, du 9 avril au 13 avril 2018.
Upvote Downvote

 
INGENICO GROUP: Q1 2018 Revenue Conference Call Invitation

2018-04-13 globenewswire
A press release and a presentation will be available on www.ingenico.com prior to the call at (5:40pm).
Upvote Downvote

 
The Cure for Hangovers in Fintech M&A? More Fintech M&A - Bloomberg

2018-04-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
INGENICO GROUP : Déclaration des opérations d'achats d'actions réalisées dans les conditions de l'article 5 §2 du règlement (UE) n° 596/2014 du 16 avril 2014 sur les abus de marché

2018-04-09 globenewswire
Conformément à la réglementation applicable, Ingenico Group déclare avoir effectué les opérations d'achat d'actions suivantes dans les conditions de l'article 5 §2 du règlement (UE) n°596/2014, du 29 mars au 6 avril 2018.
Upvote Downvote

 
INGENICO GROUP : Informations relatives au nombre total de droits de vote et d'actions composant le capital au 31 mars 2018

2018-04-05 globenewswire
INGENICO GROUP Société Anonyme au capital de 62.363.114 euros Siège social : 28/32 boulevard de Grenelle 75015 Paris RCS Paris : 317 218 758
Upvote Downvote

 
INGENICO GROUP : Déclaration des opérations d'achats d'actions réalisées dans les conditions de l'article 5 §2 du règlement (UE) n° 596/2014 du 16 avril 2014 sur les abus de marché

2018-03-29 globenewswire
Déclaration des opérations d'achats d'actions réalisées dans les conditions de l'article 5 §2 du règlement (UE) n° 596/2014 du 16 avril 2014 sur les abus de marché
Upvote Downvote

 
Ingenico déploie sa solution de paiement paneuropéenne et omnicanal pour le groupe ADEO

2018-03-21 globenewswire
Ingenico Group (Euronext : FR0000125346 - ING), leader mondial des solutions de paiement intégrées, a été retenu par ADEO pour le déploiement de sa solution d'acceptation de paiement omnicanal et paneuropéenne. Cette solution permettra de mutualiser les transactions effectuées dans l'univers ADEO en magasin ou en ligne dans plusieurs pays en Europe. ADEO, leader européen du marché du bricolage, fédère de prestigieuses enseignes comme Leroy Merlin, Bricoman ou Zodio.
Upvote Downvote

 
Ingenico rolls out its pan-European omnichannel payment solution for ADEO

2018-03-21 globenewswire
Ingenico Group (Euronext: FR0000125346 - ING), the global leader in seamless payment, has been chosen by ADEO to roll out its pan-European omnichannel payment acceptance solution. This solution will allow the centralized management of ADEO's transactions, both in-store and online, across several European countries. ADEO, the European leader on the DIY market, encompasses prestigious brands such as Leroy Merlin, Bricoman or Zodio.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...